| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,460,410 | -8,461,748 |
| Stock-based compensation | 426,409 | 393,130 |
| Prepaid expenses and deposits | 643,007 | 794,872 |
| Other receivables | -681,550 | -672,368 |
| Related party payable | -1,382,185 | -1,053,869 |
| Accounts payable and accrued expenses | -89,307 | 513,917 |
| Deferred revenue | 1,352,975 | 1,352,975 |
| Net cash used in operating activities | -10,113,975 | -7,378,099 |
| Proceeds from issuance of common stock, net | 9,863,883 | - |
| Proceeds from exercise of warrants and stock options | 605 | 605 |
| Net cash provided by financing activities | 9,864,488 | 605 |
| Net decrease in cash, cash equivalents, and restricted cash | -249,487 | -7,377,494 |
| Cash and cash equivalents at beginning of period | 19,192,440 | - |
| Cash and cash equivalents at end of period | 18,942,953 | - |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)